摘要
目的:研究β2肾上腺素受体(ADR2)基因多态性和美托洛尔引起的血脂代谢紊乱的相关性。方法:美托洛尔100 mg.d-1单药治疗高血压患者,测量治疗前后血甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)浓度,分析TG/HDL-C比值的变化;并利用测序及PCR-RFLP方法进行基因多态性分析。结果:治疗后TG浓度和TG/HDL-C比值明显升高;携带ADR2的Arg16Arg基因型患者治疗前后血TG浓度和TG/HDL-C比值的差值明显小于Arg16Gly或Gly16Gly者。结论:ADR2的Arg16Gly多态性有可能是美托洛尔治疗后TG/HDL-C比值变化的标记物。
Objective： To investigate the relationship between β2-adrenergic receptor（ADR2） polymorphisms and metoprolol-induced dyslipidemia.Methods： Hypertensive patients received metoprolol monotherapy（100 mg once daily） for two months.The lipid levels were determined before and after the treatment,and genotyping was preformed by PCR-RFLP or sequencing.Results： After treatment,the levels of TG（triglyceridemia） and TG/HDL-C（high-density lipoprotein cholesterol） ratio increased significantly.In patients with the Arg16Arg genotype in ADR2 gene,the differences of TG and TG/HDL before and after treatment were smaller than those with Arg16Gly and Gly16Gly genotype.Conclusion： The Arg16Gly polymorphism in the ADR2 gene may be a candidate predictor for the change in TG/HDL-C induced by metoprolol monotherapy in Chinese Han hypertensive patients.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2010年第18期1661-1665,共5页
Chinese Journal of New Drugs
基金
“重大新药创制”科技重大专项《创新药物临床研究技术平台建设》(2008ZX09312-018)
